Signs of Morphine Use Disorder
In the morphine population specifically, use disorder rarely looks like the textbook picture people imagine. There are no track marks, no missed work, no dramatic decline — at least not at first. What there is, often, is a slow drift in the relationship between the patient and the medication, where the medication quietly starts running the day instead of the other way around. Many of the most clinically significant signs are things the patient or family only name in hindsight.
- Dose escalation beyond what was prescribed. Taking an extra sustained-release tablet on bad days. Using two breakthrough doses when the plan calls for one. Running 30-day supplies in 24 or 21 days. Tolerance is expected with long-term opioid therapy, but a repeating pattern of using more than prescribed is a clinical signal.
- Resistance to tapering conversations. Your doctor brings up reducing the dose and you notice yourself finding reasons it’s not the right time — the pain is flaring, there’s a family event coming up, work is stressful, you’re not sleeping. Every reason is real. But if this has happened with every taper attempt for years, the pattern itself is the signal.
- Using the medication for things beyond physical pain. The morphine helps you sleep. The morphine helps you tolerate a difficult visit with a family member. The morphine takes the edge off grief, anxiety, or boredom. None of these are original indications, and they’re common reasons patients describe when asked carefully about their use.
- Early refill requests. Running out before the refill date. Calling the pharmacy for “vacation overrides.” Lost prescriptions that have to be replaced. The occasional legitimate early need happens; a repeating pattern is different.
- Hiding use from family or prescribers. Taking an extra dose in the bathroom. Not mentioning the amount actually taken at a medical visit. Keeping the number in the bottle a private count only you know. Concealment is one of the clearest behavioral markers, and one patients often recognize in themselves before clinicians do.
- Continued use after the original indication has resolved. The cancer is in remission. The surgery healed. The acute flare is over. The rehab course ended. And the morphine is still being refilled, often without a recent conversation about why.
- Withdrawal symptoms between doses. Restlessness, sweating, yawning, muscle aches, anxiety, or GI upset that resolves when the next dose is taken. This is physical dependence, and in long-term morphine therapy it can exist whether or not use disorder is present — but when it’s driving use, the line has moved.
- Pain that’s become harder to distinguish from withdrawal. Many long-term morphine patients develop opioid-induced hyperalgesia — a paradoxical increase in pain sensitivity from chronic opioid exposure. The symptom that feels like the original pain returning may actually be withdrawal or hyperalgesia, not tissue pain. The medication is treating something it also created.
- Loss of control. Deciding to take only one breakthrough dose today and taking three. Deciding to stretch the prescription and not being able to. Making promises about dose limits to yourself or a spouse and not keeping them.
For patients who developed dependence in the context of legitimate chronic or cancer pain, the line between “appropriate long-term opioid therapy” and “opioid use disorder” can genuinely be blurry. DSM-5 criteria don’t automatically apply the way they do in a recreational-use pattern — tolerance and withdrawal, for instance, are expected consequences of medically supervised long-term therapy and are excluded from the diagnosis in that context. What remains diagnostic are the behavioral and functional criteria: loss of control, craving, use despite consequences, using in situations where it’s hazardous, and repeated unsuccessful attempts to cut down. A careful clinical interview is what sorts this out. A checklist won’t.
Morphine Withdrawal: Timeline and Symptoms
Morphine withdrawal is uncomfortable but, in otherwise healthy adults, not typically life-threatening the way alcohol or benzodiazepine withdrawal can be. For patients on chronic morphine therapy — especially extended-release formulations — the timeline and texture of withdrawal are distinctive.
First, onset is slower than with short-acting opioids. Immediate-release morphine (Roxanol, MSIR) has a half-life of 2–4 hours and produces withdrawal onset similar to hydrocodone — 6–12 hours after last dose. Extended-release morphine is a different animal: MS Contin, Kadian, and Avinza are engineered for 12–24 hour dosing, and withdrawal typically takes 12–24 hours to begin and can be blunted for the first day as residual medication is still releasing. That makes the induction timing for buprenorphine different from what’s used for fentanyl or hydrocodone patients.
Second, protracted withdrawal is more common in patients who have been on morphine for multiple years. The body’s endogenous opioid system adapts to long exposure, and re-regulation after discontinuation can stretch over weeks to many months. Low energy, mood changes, sleep disturbance, and intermittent cravings are the usual protracted pattern, and MAT with buprenorphine sharply compresses this phase compared with unmedicated abstinence.
Third, the psychological component is often more prominent than in illicit-opioid withdrawal. Many morphine patients have a real, grounded fear of pain returning. That fear is not irrational — their original indication may still carry residual pain, and their experience of being without opioids may be colored by memories of pre-treatment suffering. The fear itself intensifies symptom perception. Clinically, this means withdrawal management in this cohort needs to address the pain-return concern as directly and honestly as it addresses the physical symptoms.
A general timeline for morphine withdrawal looks like this:
- First 12 to 24 hours after last dose. For extended-release morphine, the first wave is delayed compared with short-acting opioids. Early symptoms: anxiety, restlessness, muscle aches, yawning, watery eyes, runny nose, sweating, and craving. Patients on immediate-release morphine can start 6–12 hours after last dose.
- Day 1 to day 3 (peak). Full symptom picture: nausea, vomiting, diarrhea, abdominal cramping, chills alternating with sweating, dilated pupils, goosebumps, muscle and bone aches, profound fatigue, intense cravings, and the return or amplification of any underlying pain. Heart rate and blood pressure rise. Sleep is severely disrupted. Most unmedicated attempts to stop fail in this window.
- Day 3 to day 7. Acute GI symptoms gradually subside. Appetite may start to return. Sleep remains fragmented. Cravings stay strong. Low mood and anxiety often peak here as the body begins re-regulating.
- Week 2 and beyond (post-acute). For short-term morphine users, most acute symptoms have cleared. For long-term users, post-acute withdrawal can persist: low energy, difficulty concentrating, mood changes, anhedonia, sleep disturbance, and intermittent cravings over weeks to months. This is the slow nervous-system re-calibration, not a sign treatment is failing. MAT dramatically shortens it.
An important clinical point: do not stop morphine on your own if you’ve been on it long-term, especially at moderate or higher MME. The risk is not primarily life-threatening withdrawal — it’s relapse to high-dose use after your tolerance has dropped, which is the highest-risk moment for overdose. A supervised transition is dramatically safer than a cold-turkey attempt.
How We Treat Morphine Addiction
At Restoration Recovery, morphine use disorder is treated with a combination of medication and psychosocial support. For the chronic-pain origin cohort, buprenorphine-based MAT has a distinct advantage over full-agonist tapering: it addresses the dependence and the pain simultaneously, because buprenorphine is itself a potent analgesic (partial mu-receptor agonist with kappa-receptor activity). For many patients, this is the difference between “stop using an opioid you need for pain” and “transition to an opioid that treats both the pain and the dependence with a much safer pharmacologic profile.” The medication options are:
- Suboxone (daily film or tablet). A combination of buprenorphine and naloxone taken sublingually — available as a dissolving film or tablet placed under the tongue. Buprenorphine stabilizes cravings, prevents withdrawal, and provides real analgesia at the same receptors morphine was acting on — but with a ceiling effect on euphoria and respiratory depression. For chronic-pain patients, the ceiling effect matters: it’s the feature that keeps buprenorphine safer than morphine even as doses change over time. The naloxone component is inactive when the medication is taken correctly; it’s included to discourage misuse via injection.
- Sublocade (monthly injection). A long-acting extended-release form of buprenorphine administered once per month at our clinics. For morphine patients who have spent years on a daily medication ritual, Sublocade’s once-monthly cadence can be psychologically freeing — no pill box, no timing, no daily cue. Steady blood levels throughout the month also smooth out the mood and energy fluctuations many patients report on daily regimens. Per FDA labeling, Sublocade requires at least 7 days of transmucosal buprenorphine (Suboxone) before the first injection.
- Brixadi (weekly, bi-weekly, or monthly injection). Another extended-release buprenorphine injection, with flexible dosing intervals. Brixadi’s weekly and bi-weekly options are useful for patients who are still titrating to the right maintenance dose, or who prefer a shorter interval than Sublocade’s monthly cadence. Like Sublocade, Brixadi is ordered per-patient and administered at a follow-up visit once the medication arrives.
Medication alone is effective; medication paired with behavioral support is more effective. We pair MAT with:
- Individual counseling with licensed therapists experienced in substance use disorder. Counseling for the chronic-pain origin cohort often surfaces material specific to this pathway — grief over health events that triggered the prescription, fear of pain returning, shame about needing medication to function, complicated feelings about the original prescribing provider, and for cancer survivors specifically, the unresolved emotional weight of the illness itself.
- Certified peer support from specialists who have lived experience with recovery. For the older chronic-pain cohort, peer support can look different than it does for the street-opioid cohort — the shared story is more often about medication dependence that developed inside the medical system, not about illicit use. We match patients to peers whose experience aligns.
- Intensive outpatient programming (IOP) for patients who benefit from a more structured treatment schedule — delivered in a group format by design. IOP is the only group-setting service we offer, and it’s a separate, structured program rather than an informal group activity.
- Integrated care for co-occurring conditions, including anxiety, depression, trauma, chronic pain, and hepatitis C. Anxiety and depression are particularly common in long-term morphine patients — often predating the opioid therapy and worsening through it. We address them rather than handing them off to a separate referral track.
Pain Plan Rebuild
For patients whose morphine use began in a legitimate pain context, stopping the morphine is rarely the full answer. The pain doesn’t automatically resolve. The injury, the cancer history, the degenerative condition, the post-surgical nerve damage — whatever was treated with opioids originally is often still there, in some reduced form. Sustainable recovery requires restructuring the entire pain care plan, not just subtracting the morphine.
At intake we map out what that rebuild looks like in your specific case. Common components include: transitioning the opioid portion of the regimen to buprenorphine (which carries analgesic properties of its own); introducing or optimizing non-opioid pharmacotherapy — neuropathic agents, NSAIDs where tolerated, acetaminophen, topical agents, low-dose antidepressants with analgesic effect; coordinating with physical therapy; addressing sleep and mood drivers of pain perception; and referring to interventional pain specialists where procedural options (nerve blocks, epidural injections, radiofrequency ablation, spinal cord stimulation) are appropriate. For patients under active cancer survivorship care, we coordinate with oncology.
You do not have to have this plan figured out before your first visit. That’s what the first visit is for.
Coordination with Pain Providers
A large share of our morphine patients arrive with an active pain management relationship elsewhere — a pain clinic, a long-standing primary care provider, an oncologist, a palliative care team. We coordinate with those providers rather than replacing them. The goal is one unified plan among our clinic, your pain provider, and you — not two parallel medication lists that contradict each other.
In practice, coordination usually means: a release of information from you allowing direct provider-to-provider communication; a conversation about the opioid transition plan so your pain provider knows what we’re doing and when; and clear agreement about who is prescribing what going forward. Some pain providers are comfortable continuing non-opioid pain care while we manage the buprenorphine; others prefer to step back on the pain medication side entirely. Either configuration works. What does not work is two uncoordinated plans. If your pain provider has concerns about the transition, we’ll talk with them directly — and often those conversations resolve quickly once everyone is looking at the same picture.
Restoration Recovery is an outpatient clinic. We do not provide medical detox or residential care. For most patients with morphine use disorder, a formal inpatient detox is not required — medication-assisted treatment can begin at the appropriate COWS-score window after last dose, under clinical supervision. For patients who need a higher level of care before starting outpatient MAT, we coordinate with regional referral partners.
What to Expect at Your First Appointment
Your first visit typically lasts 60 to 120 minutes and follows a four-step clinical flow. For the chronic-pain / palliative / cancer-survivor cohort, the intake emphasis is different from a street-opioid intake, and the visit is structured accordingly:
- Intake. You’ll complete paperwork and a clinical intake. For opioid use disorder, this includes a DSM-5 assessment — adapted for patients on supervised chronic opioid therapy, where tolerance and withdrawal are expected features of treatment and don’t count toward the diagnosis — and a COWS (Clinical Opiate Withdrawal Scale) score to measure your current withdrawal state. For morphine patients, intake also captures: the original pain indication and its current status, your complete list of current prescribers and medications, previous taper attempts and outcomes, and any co-occurring conditions (chronic pain, anxiety, depression, cancer history) that shape the treatment plan.
- Counseling. You’ll meet with a counselor to discuss your substance use history — including the original clinical context — any previous treatment, your goals, and any specific concerns you have about the transition. For patients in active cancer survivorship, recent loss, or ongoing chronic pain, this conversation is where the emotional picture gets mapped alongside the medical one. This is also where we document any active pain management relationship so coordination can begin.
- Doctor evaluation. A medical provider reviews your intake, COWS score, medication list, and counselor notes. They walk you through the medication options (Suboxone, Sublocade, Brixadi), explain onset, side effects, and timing, and answer your questions. For long-term morphine patients — especially those on extended-release formulations or high MME — the induction timing discussion is more detailed than for short-acting opioids: we’re often looking at a longer pre-induction interval to avoid precipitated withdrawal.
- Prescription (and injection ordering, if chosen). If clinically appropriate, you leave the same day with a Suboxone prescription. If you prefer the extended-release route, your provider will order Sublocade or Brixadi during this visit — we don’t stock injections on-site — and you’ll continue on Suboxone as a bridge. Your injection appointment is scheduled for a follow-up once the medication arrives, typically after a short stabilization period on Suboxone (Sublocade’s FDA label requires at least 7 days of transmucosal buprenorphine before the first injection).
Bring a valid photo ID, your insurance card if applicable, and a complete list of current medications — including the specific morphine product (MS Contin, Kadian, Avinza, immediate-release), dose, dosing interval, and any breakthrough medication. Also bring contact information for other active prescribers (pain specialist, oncologist, primary care) so coordination can start right away. If you’d like to see the full process walked through step by step before your visit, our guide on what to expect at your first Suboxone appointment covers it in more detail.
Why Medication-Assisted Treatment Works for Morphine
For many patients, the fear of withdrawal and the fear of pain return are what keep them stuck. MAT removes the first — buprenorphine prevents withdrawal rather than forcing patients to endure it — and substantially addresses the second, because buprenorphine is itself a clinically meaningful analgesic. For the chronic-pain cohort, that combination is the most important reason this medication class works where a straight morphine taper often doesn’t.
Medication-assisted treatment is endorsed as the standard of care for opioid use disorder by the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institute on Drug Abuse (NIDA), the American Society of Addiction Medicine (ASAM), and the World Health Organization. Buprenorphine’s analgesic properties are well-established — it is used off-label for chronic pain in settings without a dependence component, and the Belbuca product (buccal buprenorphine) is FDA-approved specifically for chronic pain management. The dual indication is part of why this medication fits this patient population so well.
Large-scale evidence shows that patients with opioid use disorder who receive buprenorphine-based MAT:
- Experience more than a 50 percent reduction in the risk of fatal opioid overdose
- Stay in treatment significantly longer than those receiving counseling alone
- Report fewer cravings and lower rates of continued opioid use
- Are more likely to maintain employment and stable living situations during recovery
- Report comparable or better pain control on buprenorphine than on prior full-agonist regimens, particularly when paired with non-opioid pain strategies
There is a specific clinical point worth naming for this cohort. Buprenorphine’s partial-agonist pharmacology gives it a ceiling effect on euphoria and respiratory depression that full agonists like morphine, oxycodone, and fentanyl do not have. For older patients — the demographic that now makes up the fastest-growing share of long-term opioid users — that ceiling is a significant safety feature. Respiratory depression in sleep, sedation-related falls, and interactions with benzodiazepines or alcohol are all softer on buprenorphine than on morphine at equivalent analgesic effect. MAT is not a replacement of one drug with another; it is a pharmacologic upgrade to a medication with a materially safer profile in the exact risk categories this population cares about.
Why Restoration Recovery
Choosing where to start treatment matters, and for the chronic-pain / cancer-survivor / long-term-prescription cohort, the clinical feel of the clinic matters as much as the medication list. Restoration Recovery was built around both.
- Chattanooga’s longest-running outpatient addiction treatment clinic. Our providers have decades of experience treating opioid and substance use disorders in Southeast Tennessee — including the full arc from the pre-2012 prescribing peak, through the prescribing-rate collapse, into the current era where the remaining long-term opioid population is increasingly older and medically complex. We have seen every version of this.
- CARF accredited. The Commission on Accreditation of Rehabilitation Facilities is the gold standard for outpatient addiction care — our accreditation is reviewed on an ongoing basis, not a one-time stamp.
- Non-shaming clinical culture. For morphine patients whose dependence developed while following provider instructions, the tone of care matters. We do not lecture. We do not moralize. Physical dependence after years of clinically indicated opioid therapy is a medical reality, not a character finding. The conversation at our clinic is about the plan forward, not who did what wrong.
- Four clinic locations across Southeast Tennessee and North Georgia, with telehealth follow-up available for established patients. Several of our locations are convenient for patients coordinating care with oncology, pain management, or primary care elsewhere in the region.
- Most major insurance accepted — TennCare, Georgia Medicaid, commercial plans, Medicare, and supplemental Medicare. Medicare coverage is especially relevant for this population; our patient services team verifies your benefits before your first visit so there are no surprises.
- Same-day Suboxone appointments in most cases. You don’t have to wait weeks to start.
- One integrated team. Medical providers, counselors, certified peer support specialists, and psychiatric care under one roof — not parallel referral tracks that leave you coordinating your own care. For patients with co-occurring chronic pain, anxiety, depression, or hepatitis C, this matters.
- Licensed in both states. Licensed in Tennessee and Georgia, HIPAA compliant, 42 CFR Part 2 compliant — your treatment is confidential from the first phone call, which matters especially for patients who have active relationships with other prescribers and employers.
Insurance and Access
Restoration Recovery accepts most major insurance plans, including TennCare, Georgia Medicaid, a broad range of commercial plans, and Medicare (plus supplemental Medicare plans). For the morphine patient population — which skews toward older adults on Medicare or Medicare Advantage plans, and toward cancer survivors with established commercial coverage — our patient services team can verify your benefits before your first appointment so you know exactly what to expect in terms of cost.
If you do not have insurance, contact us anyway. We can help you explore options and will walk you through self-pay pricing. For a full list of accepted carriers and details on the verification process, visit our insurance page.
Four Clinic Locations
We operate four outpatient clinics across Southeast Tennessee and North Georgia. All locations offer morphine addiction treatment with same-day appointments in most cases:
- Chattanooga, TN — 6141 Shallowford Rd, Suite 100, Chattanooga, TN 37421
- Cleveland, TN — Serving Bradley County and surrounding areas
- Soddy-Daisy, TN — Serving Hamilton County north and the Sequatchie Valley
- Ringgold, GA — Serving Catoosa County and Northwest Georgia
Telehealth follow-up visits are available for established patients who have completed their initial in-person evaluation — a particularly useful option for older patients, mobility-limited patients, or patients coordinating care across multiple specialists. For directions, hours, and contact information, visit our locations page.
Frequently Asked Questions
I have real pain. Does starting MAT mean I’ll be left in pain?
No. Buprenorphine — the active medication in Suboxone, Sublocade, and Brixadi — is itself a potent analgesic. It partially activates the same opioid receptors morphine was acting on, without the same euphoria or the same overdose risk. For many patients, pain is actually better controlled on buprenorphine than on escalating morphine doses, because the nervous system stops cycling between peak and trough every few hours. We also coordinate with your pain provider when appropriate so there’s one consistent plan. MAT does not mean abandoning pain care; it means restructuring it around a safer medication and, often, a fuller set of non-opioid strategies.
I’ve been on morphine for years since my cancer treatment. Do I really have an “addiction”?
Physical dependence is not the same as moral failing, and the word “addiction” is often not the most useful clinical framing for this cohort. Morphine produces dependence in any patient taking it long-term, regardless of why they started — that’s pharmacology, not character. If your cancer treatment ended months or years ago and the morphine is still running your schedule, that’s worth a clinical conversation. Use disorder exists on a spectrum, from mild to severe, and many long-term cancer survivors fall somewhere on it. The goal isn’t to apply a label; it’s to build a plan for transitioning off morphine safely while keeping residual pain managed. Buprenorphine is often well-suited for exactly that transition.
Can I keep my pain doctor if I start treatment here?
Yes, and in most cases you should. We coordinate with pain providers rather than replacing them. The ideal picture is one unified plan among our clinic, your pain specialist, and you. What typically changes is the medication strategy — we transition the opioid component from morphine to buprenorphine — while your pain provider stays involved in the non-opioid and procedural side of your care (interventional procedures, neuropathic medications, physical therapy referrals). Some pain providers prefer to step back on medication management once MAT begins; others continue non-opioid care in parallel. Both configurations work. If your pain provider has questions or concerns about the transition, we’ll talk with them directly.
What is MME and why does my doctor keep mentioning it?
MME stands for morphine milligram equivalents. It’s the unit clinicians use to compare doses across different opioids by converting them to the equivalent dose of morphine. Morphine itself is the reference: 1 mg of oral morphine = 1 MME. Oxycodone converts at 1.5 MME per mg, hydrocodone at 1.0, and transdermal fentanyl is much higher per microgram. The 2022 CDC opioid prescribing guideline identifies 50 MME/day as the threshold where overdose risk roughly doubles, and 90+ MME/day as the range where risk climbs to up to nine times the rate at under 20 MME/day. If your provider is discussing your MME, they are reading the combined opioid risk from your entire medication list, not just one prescription.
Can I just taper morphine slowly instead of switching to Suboxone?
Sometimes. A slow, clinically supervised morphine taper is a legitimate option for some patients — particularly those on moderate doses, for a short to medium duration, with no features of opioid use disorder and stable pain control. It is not a good option for everyone. For patients with significant physical dependence, escalating use, concealed use, opioid-induced hyperalgesia, or DSM-5 features of use disorder, buprenorphine-based MAT has substantially stronger evidence: it stabilizes cravings, prevents withdrawal cycling, addresses residual pain, and is much easier to sustain long-term than a prolonged taper. At intake we walk through both paths honestly. The right answer depends on your specific dose, duration, pain picture, prior taper attempts, and the overall clinical story.
I’m older and on morphine for back pain. Am I the right fit for this clinic?
Yes. A meaningful share of our opioid caseload is older adults — patients in their 60s, 70s, and beyond — who started morphine for legitimate chronic pain and stayed on it longer than originally planned. The clinical picture in older patients is different from the illicit-opioid cohort: slower metabolism, more polypharmacy, more sensitivity to sedation and respiratory depression, greater fall risk, and often real residual pain that still deserves treatment. We take all of that into account. Transitioning to buprenorphine in older adults is well-studied and generally well-tolerated, and many patients report meaningful improvement in day-to-day function — clearer thinking, better sleep architecture, more even mood — once the morphine peak-and-trough cycle ends. The clinic is set up for this population.
Take the Next Step
Morphine dependence is treatable, and the right plan starts with a conversation — not a commitment, not a label, not a confession. You don’t have to figure this out alone, you don’t need to have all the answers before you call, and you don’t need to stop the medication on your own before your first appointment. In fact, please don’t. Our team will walk you through the process from your first phone call to your first visit and every follow-up after that, and we’ll coordinate directly with your pain provider or oncology team if that’s part of your picture.
Same-day appointments are available in most cases. Contact us today to schedule your evaluation, or call 423-498-2000 to speak with our team directly.
